Biogen Inc. has announced the initiation of a Phase 3 study, named PROMINENT, to assess the efficacy and safety of felzartamab in the treatment of primary membranous nephropathy $(PMN)$. This global study will compare felzartamab, an investigational anti-CD38 monoclonal antibody, with tacrolimus in adults with PMN, a rare immune-mediated kidney disease currently lacking approved therapies. The study aims to address the unmet medical need for this condition, which affects approximately 36,000 patients in the U.S. alone. This marks the third Phase 3 trial of felzartamab initiated by Biogen this year, following studies for late antibody-mediated rejection in adult kidney transplant recipients and IgA nephropathy. The results of the PROMINENT study have not yet been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。